WO2022123947A1 - 中和可能コバレントドラッグ - Google Patents
中和可能コバレントドラッグ Download PDFInfo
- Publication number
- WO2022123947A1 WO2022123947A1 PCT/JP2021/039891 JP2021039891W WO2022123947A1 WO 2022123947 A1 WO2022123947 A1 WO 2022123947A1 JP 2021039891 W JP2021039891 W JP 2021039891W WO 2022123947 A1 WO2022123947 A1 WO 2022123947A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- linker
- group
- aptamer
- neutralizable
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 229940079593 drug Drugs 0.000 title claims abstract description 81
- 108091008104 nucleic acid aptamers Proteins 0.000 claims abstract description 118
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 230000000295 complement effect Effects 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 38
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 125000005647 linker group Chemical group 0.000 claims description 136
- 108091023037 Aptamer Proteins 0.000 claims description 106
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 85
- 238000006243 chemical reaction Methods 0.000 claims description 49
- 239000003146 anticoagulant agent Substances 0.000 claims description 37
- 229940127219 anticoagulant drug Drugs 0.000 claims description 37
- 125000000732 arylene group Chemical group 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 11
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 10
- MOOGIHKPTRJVRV-ZHVXJWHRSA-N chembl1814697 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(N)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(N)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(N)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COC(=O)CCCC[C@H]2[C@H]3NC(=O)N[C@H]3CS2)[C@@H](OP(N)(=O)OC[C@H]2O[C@H]([C@H](OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)O)C2)N2C3=C(C(NC(N)=N3)=O)N=C2)C1 MOOGIHKPTRJVRV-ZHVXJWHRSA-N 0.000 claims description 7
- 150000001540 azides Chemical class 0.000 claims description 6
- 230000023555 blood coagulation Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- LADFAOKPINUFBB-TWPNXFTKSA-N 5'-GGTTGGTGTGGTTGG-3' Chemical compound Cc1cn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(O)=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)[C@@H](COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3CO)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)O2)c(=O)[nH]c1=O LADFAOKPINUFBB-TWPNXFTKSA-N 0.000 claims description 3
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical group FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 abstract description 3
- 230000027455 binding Effects 0.000 description 66
- 108090000190 Thrombin Proteins 0.000 description 60
- 229960004072 thrombin Drugs 0.000 description 59
- 150000001345 alkine derivatives Chemical group 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- 238000006386 neutralization reaction Methods 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 14
- 108010049003 Fibrinogen Proteins 0.000 description 12
- 102000008946 Fibrinogen Human genes 0.000 description 12
- 230000015271 coagulation Effects 0.000 description 12
- 238000005345 coagulation Methods 0.000 description 12
- 229940012952 fibrinogen Drugs 0.000 description 12
- -1 polyethyleneoxy Polymers 0.000 description 12
- 102000009123 Fibrin Human genes 0.000 description 11
- 108010073385 Fibrin Proteins 0.000 description 11
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 11
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 11
- 239000000729 antidote Substances 0.000 description 11
- 229950003499 fibrin Drugs 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 238000006664 bond formation reaction Methods 0.000 description 8
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 8
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 125000005549 heteroarylene group Chemical group 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229940113082 thymine Drugs 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 125000004474 heteroalkylene group Chemical group 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 125000002993 cycloalkylene group Chemical group 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 150000003573 thiols Chemical group 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical group CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 4
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 4
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091008102 DNA aptamers Proteins 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000013076 target substance Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229910006095 SO2F Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- ZJJAWGLRWHRNGC-UHFFFAOYSA-N 1,2-dimethoxy-1-azacyclooct-7-yne Chemical compound COC1CCCCC#CN1OC ZJJAWGLRWHRNGC-UHFFFAOYSA-N 0.000 description 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 2
- IELMMGIVWJNLEX-UHFFFAOYSA-N 3,3-difluorocyclooctyne Chemical compound FC1(F)CCCCCC#C1 IELMMGIVWJNLEX-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- SBTXYHVTBXDKLE-UHFFFAOYSA-N bicyclo[6.1.0]non-6-yne Chemical compound C1CCCC#CC2CC21 SBTXYHVTBXDKLE-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WRADPCFZZWXOTI-BMRADRMJSA-N (9E)-10-nitrooctadecenoic acid Chemical compound CCCCCCCC\C([N+]([O-])=O)=C/CCCCCCCC(O)=O WRADPCFZZWXOTI-BMRADRMJSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QUAHTHOQWXLYFQ-UHFFFAOYSA-N 3-fluorocyclooctyne Chemical compound FC1CCCCCC#C1 QUAHTHOQWXLYFQ-UHFFFAOYSA-N 0.000 description 1
- RWHNIEOAPNZZGI-UHFFFAOYSA-N 4-(2-bromoacetyl)benzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=CC=C(C(CBr)=O)C=C1 RWHNIEOAPNZZGI-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- DTPBBABJEIMGQV-UHFFFAOYSA-N 5,6-didehydro-7,8,9,10-tetrahydrobenzo[8]annulene Chemical compound C1#CCCCCC2=CC=CC=C21 DTPBBABJEIMGQV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108091081406 G-quadruplex Proteins 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- KGRSZSIPIKLUNT-UHFFFAOYSA-N O=C=C1C=CC=CC1S(F)(=O)=O Chemical compound O=C=C1C=CC=CC1S(F)(=O)=O KGRSZSIPIKLUNT-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004721 Polyphenylene oxide Chemical group 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 108020004422 Riboswitch Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 238000010461 azide-alkyne cycloaddition reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- OIBMEBLCOQCFIT-UHFFFAOYSA-N ethanesulfonyl fluoride Chemical compound CCS(F)(=O)=O OIBMEBLCOQCFIT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000570 polyether Chemical group 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- XXYIANZGUOSQHY-XLPZGREQSA-N thymidine 3'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)C1 XXYIANZGUOSQHY-XLPZGREQSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000007817 turbidimetric assay Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
Definitions
- the present disclosure relates to target-specific binding compounds and compositions that are useful as pharmaceuticals or biochemical tools.
- covalent drugs that specifically form covalent bonds with target proteins has been in the limelight in recent years (Non-Patent Document 1). Based on the formation of covalent bonds, covalent drugs can exert drug effects semi-permanently. Next-generation drugs that can improve patient quality of life because covalent drugs can be effective at lower doses and / or lower doses compared to conventional (ie, non-covalent) drugs. It is attracting attention as a drug candidate.
- Non-Patent Documents 2 and 3 covalent modality based on various molecules including small molecules and peptides has been developed (Non-Patent Documents 2 and 3), but it enables efficient neutralization, detoxification, and / or drug efficacy control. There is no covalent modality to do.
- Non-Patent Document 4 introduces a sulfonylfluoride group into the 5'end of the library of the SELEX (Systematic Evolution of Ligands by Exponential enrichment) method and performs SELEX screening. As a result, it binds to the epidermal growth factor receptor (EGFR). It is reported that a DNA aptamer having the ability was obtained. However, in Non-Patent Document 4, although the aptamer-specific target binding ability, that is, the docking ability to the target EGFR was confirmed, it seems that the ability to form a covalent bond to the EGFR was not sufficiently verified.
- SELEX Systematic Evolution of Ligands by Exponential enrichment
- the present disclosure provides a novel drug modality that at least partially overcomes the shortcomings of conventional covalent drugs.
- the present disclosure provides aptamer-type drugs that can have altered pharmacokinetics.
- a neutralizable covalent drug compound comprising a nucleic acid aptamer and a fluorinated sulfonyl group linked to the nucleic acid aptamer via an azido-alkyne click chemistry reaction.
- the aptamer and the fluorinated sulfonyl group are linked by a linker containing a linking moiety formed by the azido-alkyne click chemistry reaction.
- Neutralizable covalent drug compound [2]
- the linker is represented by the formula -L 1 -Y-L 2- , where Y is the linking moiety formed by the azido-alkyne click chemistry reaction and L 1 is the nucleic acid aptamer.
- L 2 is the second linker moiety to be attached to the fluorinated sulfonyl group.
- the neutralizable covalent drug compound according to [1], wherein the terminal portion of the second linker moiety that binds to the fluorinated sulfonyl group is arylene.
- the terminal moiety arylene that binds to the fluorinated sulfonyl group is provided in the structure below.
- [4] The neutralizable covalent drug compound according to any one of [1] to [3], wherein the linker is bound to a nucleobase in the nucleic acid aptamer.
- [5] The nucleic acid aptamer 5'-GGTTGGTGTGGTTGG-3' The neutralizable covalent drug compound according to any one of [1] to [4], which is a thrombin-binding aptamer having the sequence of (SEQ ID NO: 1).
- a pharmaceutical composition comprising the neutralizable covalent drug compound according to any one of [1] to [5].
- [8] The anticoagulant according to [7] for use in a method for preventing or suppressing blood coagulation in a patient, wherein the method administers the anticoagulant to the patient and the anticoagulant.
- An anticoagulant comprising further administration of an oligonucleotide complementary to said nucleic acid aptamer after administration of the agent.
- a) (a1) A nucleic acid aptamer specific to the target protein to which an alkynyl group, a cycloalkynyl group, or a heterocycloalkynyl group, or (a2) an azide group is linked or bound, and b) The corresponding (b1) azido group, or (b2) alkynyl group, cycloalkynyl group, or a warhead compound having a structure in which a heterocycloalkynyl group and a fluorinated sulfonyl group are linked or bonded is reacted.
- the Warhead compound comprises a second linker linking the fluorinated sulfonyl group with the azide or alkynyl group, cycloalkynyl group, or heterocycloalkynyl group.
- the terminal portion of the second linker that binds to the fluorinated sulfonyl group is arylene.
- the terminal moiety arylene that binds to the fluorinated sulfonyl group is provided in the structure below.
- a neutralizable covalent drug compound comprising a nucleic acid aptamer and a fluorinated sulfonyl group linked to the nucleic acid aptamer via a linker, wherein the terminal portion of the linker that binds to the fluorinated sulfonyl group is arylene.
- the terminal moiety arylene that binds to the fluorinated sulfonyl group is provided in the structure below.
- the compounds and compositions according to the embodiments of the present disclosure not only have the properties of a covalent drug, but can also control the efficacy at a desired timing and prevent, eliminate or detoxify potential side effects or toxicity. Therefore, they can be useful as covalent drugs that embody new drug modality.
- the modality enhances the safety of covalent drugs and can therefore accelerate the application of covalent drugs in medicine.
- FIG. 1 is HPLC data showing the efficiency of introduction of a fluorinated sulfonyl group into a thrombin-bound aptamer (TBA) with linkers bound at different positions.
- FIG. 2 is data from a mobility shift experiment showing whether TBA to which a fluorinated sulfonyl group is linked forms a covalent bond to a target.
- FIG. 3A shows a comparison of the CD spectra of unmodified TBA, alkyne linker-modified TBA, and Warhead-modified TBA.
- (B) is data showing that Warhead-modified TBA competes with unmodified TBA for binding to thrombin.
- FIG. 1 is HPLC data showing the efficiency of introduction of a fluorinated sulfonyl group into a thrombin-bound aptamer (TBA) with linkers bound at different positions.
- FIG. 2 is data from a mobility shift experiment showing whether TBA to which a fluorinated
- FIG. 4 shows the experimental results of investigating the concentration dependence in the covalent bond formation reaction by Warhead-modified TBA.
- FIG. 5 is data showing that Warhead-modified TBA specifically binds to thrombin to form a covalent bond in the presence of serum protein, and the complementary strand specifically binds to the covalent complex. .. Complementary strands are FAM-labeled and detected by fluorescence imaging.
- FIG. 6 shows the results of investigating the inhibition of thrombin activity by TBA using the ability to generate polymerized fibrin from fibrinogen as an index.
- (A) shows the polymerization fibrin accumulation rate in the presence or absence of unmodified TBA or Warhead-modified TBA 3 .
- FIG. 7 shows the formation of covalent bonds to a target by SARS-CoV-2 spike protein binding aptamers (a, b) and VEGF binding aptamers (c) with fluorinated sulfonyl groups linked at various positions.
- 8 (a) and 8 (b) are data showing the neutralization of the warhead-modified aptamer by the complementary strand.
- the present disclosure provides, in one embodiment, a compound comprising a nucleic acid aptamer and a fluorinated sulfonyl group linked to the nucleic acid aptamer via a linker. More specifically, in one embodiment, a compound comprising a nucleic acid aptamer and a fluorinated sulfonyl group linked to the nucleic acid aptamer via an azido-alkyne click chemistry reaction is provided.
- the nucleic acid aptamer comprises a fluorinated sulfonyl group linked to the nucleic acid aptamer via a linker, the terminal portion of the linker that binds to the fluorinated sulfonyl group.
- a compound, which is arylene, is provided. In the present disclosure, these compounds may also be referred to as neutralizable covalent drug compounds. Having such a structure allows the compound to specifically recognize and bind to a target via a nucleic acid aptamer moiety and to form a covalent bond to the target via a fluorinated sulfonyl group.
- the term “drug” refers to a target substance, particularly a substance that can specifically bind to the target protein. Therefore, for example, a drug capable of binding to the active site of the target enzyme and inhibiting the enzyme activity is particularly preferable, but the drug does not necessarily have to have such an action, and is simply used as a binding label or a targeting moiety, for example. Drugs are also planned. Therefore, the term “drug” should be understood as a "binder” that can be widely used in vivo or in vitro.
- the compound of the present embodiment or the covalent drug compound can be regarded as a binder that specifically recognizes and binds to the target via the aptamer moiety.
- the target specifically recognized and bound can be a particular substance, or a number of specific substances having a common or similar structure.
- covalent drug is meant a drug that has the ability to further form covalent bonds to a target.
- nucleic acid aptamer technique itself is well known to those skilled in the art. Natural nucleic acid aptamers that are part of the riboswitch are also known, but more typical nucleic acid aptamers in technical applications are artificial nucleic acid aptamers, more specifically targeted from a library of random sequences. Nucleic acid molecules selected by screening for their ability to bind to a substance, or nucleic acid molecules obtained by partially modifying (eg, truncating and / or chemically modifying) the sequence of such selected nucleic acid molecules. These usually contain non-naturally occurring free nucleic acid fragments containing (or consisting of such sequences) non-naturally occurring sequences, or at least sequences that do not encounter the target molecule under natural conditions.
- aptamers are obtained or produced as binding to a desired target substance, inevitably, specific targets are known for each aptamer. Thus, one of ordinary skill in the art will not only be able to clearly recognize the nucleic acid aptamer, but will also be able to recognize the corresponding target.
- aptamers A large number of aptamers have been published and can be used in this embodiment. Examples include thrombin-binding aptamers, coagulation-based factor IXa-binding aptamers, factor Xa-binding aptamers, and Von-Villebrand factor-binding aptamers described in the publications referred to herein or in the publications they cite.
- Tissue factor pathway inhibitor binding aptamer Tissue factor pathway inhibitor binding aptamer, vascular endothelial cell growth factor binding aptamer, platelet-derived growth factor binding aptamer, complement protein C5 binding aptamer, nucleolin binding aptamer, CXCL12 binding aptamer, CCL2-binding aptamer, hepsidin-binding aptamer, Toll-like receptor 9
- Examples include, but are not limited to, bound aptamers, SARS-CoV-2 spike protein bound aptamers, VEGF bound aptamers and the like.
- aptamers and descriptions of existing techniques and reagents related to aptamers can be found, for example, at aptagen.com, bioanalysis-zone.com, genemedsyn.com, linaris.de, cambio.co.uk, basepairbio.com, etc. Can be done.
- Nucleic acid aptamers can specifically bind to a target substance with a binding affinity represented by a dissociation constant value K d of less than a micromolar (preferably less than 100 nanomolars, more preferably less than 10 nanomolars), according to the present embodiment.
- Nucleic acid aptamers linked with a fluorinated sulfonyl group can also maintain such specific binding capacity and affinity for the target substance.
- the binding of an aptamer to a target is usually obtained as the sum of a large number of non-covalent interactions.
- Nucleic acid aptamers can be DNA, RNA, or a combination thereof, eg, single-stranded DNA, single-stranded RNA, or a combination thereof. Some single-stranded nucleic acid aptamers form partially self-complementary strands within the molecule.
- the term nucleic acid aptamer also includes one or more nucleic acid modifications or unnatural nucleic acid moieties known to those of skill in the art, such as unnatural skeletal moieties and unnatural sugar moieties.
- nucleic acid modifications and unnatural nucleic acid moieties that can be used in aptamers, for example for nuclease resistance and other purposes, are known (Zhou et al., Nat Rev Drug Discov, 2017, 16 (3): 181-202. ). Examples include 2'-fluoromation, 2'-aminolation, 2'-O-methylation, 3'modification with inverted thymidine, phosphorothioate, LNA, and polyethylene glycol (PEG) modification. Not limited to these. Nucleic acid aptamers are typically 10 nucleotides (bases) or more, and more typically 15 nucleotides or more. Nucleic acid aptamers are typically 100 nucleotides or less, more typically 50 nucleotides or less, but can be longer.
- neutralizing means breaking the binding (or binding ability) of the drug or compound by the aptamer moiety, and "neutralizable” is such. It means that neutralization can be artificially induced. It is understood that by releasing the binding by the aptamer moiety, the pharmacological effect mediated by the binding of the aptamer moiety itself can also be released. For example, if the aptamer moiety is a drug that inhibits the enzyme by binding to the active site of the target enzyme and hindering the access of the substrate, the enzyme inhibitory effect can be canceled by neutralization. Neutralization may be partial neutralization, in which case mitigation of efficacy may be achieved rather than complete elimination of efficacy. Alternatively, if the binding of the aptamer moiety is a drug causing a side effect, the side effect can be eliminated by neutralization.
- neutralization can be performed by adding a complementary strand to the nucleic acid aptamer and interfering with the interaction structure between the aptamer and the target.
- complementary strands are sometimes referred to as antidote, but this does not necessarily mean that the drug or compound is toxic, and antidote is just for neutralization as defined above. Should be understood as an antidote. The antidote will be described in more detail later.
- neutralization means to release the bond (or binding ability) of the aptamer portion itself, and the covalent bond newly formed via the fluorinated sulfonyl group is "neutralized”. Not released (disconnected) by.
- nucleic acid aptamer moiety that has been released from binding to the target is anchored to the target molecule by a linker originating from a covalent bond formed via a fluorinated sulfonyl group. It is thought that it will be in a neutralized state.
- the fluorinated sulfonyl group is represented by the formula -SO 2F and is known to be able to react with at least serine, threonine, lysine, tyrosine, cysteine or histidine residues of the protein to form a covalent bond under physiological conditions. It is a reactive electrochemical group (Narayanan et al., Chemical Science 2015, 6 (5), 2650-2659). A reactive group that forms a covalent bond with a target in this way is sometimes called a warhead.
- a nucleic acid aptamer to which a fluorinated sulfonyl group is linked may be referred to as a "warhead modified" aptamer.
- linkers typically have a hydrocarbon-based skeleton. Hydrocarbon-based skeletons also include those that also include other atoms attached to and / or inserted into the hydrocarbon skeleton.
- linkage means a state in which two parts are indirectly bonded with another atom (s) in between, which means that the two parts are in between other atoms. It is contrasted with the state of being directly covalently bonded to each other without sandwiching.
- nucleic acid aptamer if one part (nucleic acid aptamer) is attached to one end of the linker structure and the other part (fluorinated sulfonyl group) is attached to another end of the linker structure, the two parts are "linked”.
- "Covalently linked” means that a nucleic acid aptamer and a fluorinated sulfonyl group are linked by a series of covalent bonds. That is, a nucleic acid aptamer is covalently bonded to one end of the linker and a fluorinated sulfonyl group is covalently bonded to the other end, and the main skeleton of the linker itself is also a covalent bond between atoms.
- the linker may be, for example, an alkylene having 1 to 10 carbon atoms, an alkenylene having 2 to 10 carbon atoms, an alkynylene having 2 to 10 carbon atoms, a heteroalkylene, a cycloalkylene, a heterocycloalkylene, an arylene, a heteroarylene or another divalent heterocyclic group.
- Heteroalkylenes represent carbon atoms in the alkylene skeleton replaced with one heteroatom such as an oxygen, nitrogen, or sulfur atom at each location, an ether moiety, and a polyether moiety such as polyethyleneoxy and polypropyleneoxy. Is also included. Linkers that do not contain the -S-part are also contemplated. Cycloalkylene and heterocycloalkylene represent cyclic alkylene and heteroalkylene, respectively. Heterocycloalkylenes include crown ethers.
- the groups constituting the linker include substituted and unsubstituted ones.
- alkylene, arylene, heteroarylene, heterocycle, and / or -NH- hydrogen atoms can be substituted.
- typical substituents include, but are not limited to, alkyl and alkyloxy, aryl, hydroxyl, amino, halogen, and combinations thereof having 1 to 10 carbon atoms.
- the linker in the embodiment in which the fluorinated sulfonyl group is linked to the nucleic acid aptamer via an azido-alkyne click chemistry reaction comprises a linking moiety formed by the azido-alkyne click chemistry reaction.
- Linkage moieties formed by other reactive groups and reaction mechanisms are possible in some cases, but the ligation and neutralization of nucleic acid aptamers to fluorinated sulfonyl groups is highly efficient using the azido-alkyne click chemistry reaction. Possible Covalent drug compounds can be produced.
- Non-Patent Document 4 a linker having a thiol functional group (-SH) at the tip is attached to the 5'end of the SELEX library, and a warhead compound having a structure of vinyl - SO2F is reacted with this. It was disclosed that C2H4 - SO2F , a warhead (also called ESF), was linked via a thioether to form a library, from which screening was performed to obtain a target-binding aptamer of interest.
- -SH thiol functional group
- Non-Patent Document 4 did not verify the formation of a covalent bond between the aptamer and the target protein under the complete reduction / denaturation conditions as in the examples of the present application, and it seems that the binding (docking) ability of the aptamer moiety was not performed. Regardless of its existence, the absence of covalent bond-forming ability may have been overlooked.
- the azido-alkyne click chemistry reaction itself is known, and those skilled in the art can clearly recognize the structure of the connecting portion formed by the azido-alkyne click chemistry reaction.
- a preferred example of the linking moiety formed by the azido-alkyne click chemistry reaction is a divalent group represented by the following chemical formula (I).
- the linking moiety formed by the azido-alkyne click chemistry reaction is a divalent group represented by the following general formula (II).
- the 8-membered ring may be a heterocycle in which one or more carbons not involved in fusion with other rings are replaced with non-carbon atoms such as nitrogen.
- the carbon at the binding moiety of the linker (the left binding arm in the following general formula (II)) can be replaced with nitrogen.
- the structures represented by the above formulas (II), (IIa) and (IIb) are examples of connecting moieties formed by an azido-alkyne click chemistry reaction called strain-accelerated azido-alkyne cycloaddition (SPAAC). be. Since SPAAC does not require the use of a copper catalyst, it is also called a copper-free click chemistry reaction.
- SPAAC strain-accelerated azido-alkyne cycloaddition
- the left side (left arm) of the structural formula shown above may be linked or bound to the nucleic acid aptamer, and the right side (right arm) may be linked or bound to the fluorinated sulfonyl group, or vice versa.
- the orientation of the linking moiety is reversed depending on whether the azide group is provided from the nucleic acid aptamer side or the fluorinated sulfonyl group side.
- the linker can be a combination of the groups described above.
- the nucleic acid aptamer side and / or the fluorinated sulfonyl group side is an alkylene having 1 to 10 carbon atoms and an alkenylene having 2 to 10 carbon atoms with respect to the linking portion formed by the click chemistry reaction between azido and alkyne.
- a linker linking a nucleic acid aptamer and a fluorinated sulfonyl group via an azido-alkyne click chemistry reaction can be expressed by the formula -L1 - Y - L2-, where Y is an azido-alkyne.
- the linking moiety formed by the inter-click chemistry reaction L 1 is the linker moiety that binds to the nucleic acid aptamer (corresponding to the first linker described later), and L 2 is the linker moiety that binds to the fluorinated sulfonyl group (corresponding to the first linker described later). Corresponds to the second linker described later).
- the third linker has a structure of -C ⁇ C- (CH 2 ) 4- (I) -CH 2 -CO-C 6 H 4- , where (I) is the above chemical formula. Represents (I).
- the terminal portion bonded to the fluorinated sulfonyl group is preferably arylene (for example, p-phenylene) or heterocycloalkylene (for example, 1,4-piperazinylene).
- the terminal portion bonded to the fluorinated sulfonyl group has the following structure, that is, carbonylphenylene as the structure for providing the arylene.
- L 2 (second linker moiety) may be an acetyl-benzene moiety or methylene-carbonyl-phenylene.
- the aryl-type warhead provided as a structure in which the fluorinated sulfonyl group is bonded to arylene as described above is an alkyl-type warhead used in the context of an aptamer-type covalent bond, for example, in Non-Patent Document 4. It was found that the ability to form covalent bonds to aptamer targets was significantly higher than that of heads.
- the present disclosure comprises a nucleic acid aptamer and a fluorinated sulfonyl group linked to the nucleic acid aptamer via a linker, wherein the terminal portion of the linker that binds to the fluorinated sulfonyl group is arylene.
- arylene is provided, for example, in the form of the carbonylphenylene or acetyl-benzene moiety described above.
- the linkage between the nucleic acid aptamer and the fluorinated sulfonyl group does not have to be mediated by the azido-alkyne click chemistry, and the linkage and linkage moiety formed by other reactive groups and reaction mechanisms are possible. ..
- ligation of the aryl-type warhead to a nucleic acid aptamer via an azido-alkyne click chemistry is preferable because a significant synergistic effect is obtained in the efficiency of covalent bond formation with respect to the aptamer target.
- the length and specific composition of the linker can vary depending on the design of the practitioner, but as a guide only, the carbon number of the linker can typically be in the range of 2-100, and more. It is typically in the range of 5-50. Also, as a guide only, the length of the linker, i.e., the distance between the nucleic acid aptamer and the fluorinated sulfonyl group when the linker is maximally extended, can typically be within 100 ⁇ , more typically within 50 ⁇ . Alternatively, it is within 30 ⁇ . The length of the linker can typically be 5 ⁇ or more, more typically 10 ⁇ or more.
- Increasing the length of the linker allows the fluorinated sulfonyl group to form a covalent bond to a site further away from the aptamer binding site or to a site further away from the linker binding site on the aptamer.
- a covalent bond is formed in the target molecule, but a covalent bond may be formed with another molecule existing in the vicinity of the target molecule at the time of aptamer binding.
- the linker is attached to one nucleobase in the nucleic acid aptamer.
- the linker may be attached to a non-5'end and a non-3'end, for example, an internal nucleobase.
- the linker can be attached to a 5'-end or 5'-end phosphate (ie, a phosphate group attached to the 5'end) of the nucleic acid aptamer.
- the linker may be attached to a 3'end or 3'end phosphate (ie, a phosphate group attached to the 3'end) of the nucleic acid aptamer, or the ribose ring of either nucleotide / nucleoside. Can be attached to the 3'position of (in which case a 2'-5'phosphodiester bond can be utilized).
- the linker may be attached to the 2'position of the ribose ring of any of the nucleotides / nucleosides that make up the nucleic acid aptamer.
- Nucleotides / nucleosides to which an alkyne structure or azido group can be used for azido-alkyne click chemistry reactions at these positions are available. It is commercially available or can be synthesized by those skilled in the art. In addition, a service for synthesizing an oligonucleotide of any sequence incorporating a nucleotide having an alkyne structure or an azide group linked or bonded to each of the above positions is commercially available.
- Alkin-modified or azide-modified oligonucleotides examples include Integrated DNA Technologies, Japan Genetic Research Institute, Inc., and Sigma-aldrich. Not limited to these. These structures have conventionally been used, for example, for fluorescent labeling of nucleic acids.
- the bases are adenine (A), guanine (G), inosin (I) (hypoxanthin), cytosine (C), thymine (T), and uracil. It can be any of (U), but A, C, T or U is preferable, and T or U is particularly preferable.
- the linker may be attached to the 5-position of the pyrimidine ring constituting those bases.
- the linker can be attached in such a way that the methyl group at the 5-position of the pyrimidine ring constituting the thymine base is replaced with the linker, and as a result, the structure is the same as that of U to which the linker is attached as described above.
- a state can also be referred to as a linker attached to the 5-position of the pyrimidine ring constituting the T (thymine) base.
- the linker may be attached to the 7-position of the purine ring constituting those bases. In that case, the nitrogen atom at the 7th position of the purine ring can be replaced with a carbon atom.
- the nucleic acid aptamer constituting a part of this compound is 5'-GGTTGGTGTGGTTGG-3' It is a thrombin-binding aptamer having the sequence of (SEQ ID NO: 1). That is, a compound containing a nucleic acid aptamer having the sequence of SEQ ID NO: 1 and a fluorinated sulfonyl group linked to the nucleic acid aptamer via a linker, or a neutralizable covalent drug compound is provided.
- Thrombin is an enzyme involved in blood coagulation by cleaving fibrinogen to produce fibrin.
- thrombin-binding nucleic acid aptamer itself is described in Bock et al., Nature, 1992, 355, 564-566. Further nucleic acid sequences may be added to the 5'and / or 3'sides of the above sequence. In fact, Bock et al. Found clonbin-binding ability in screening from nucleic acid populations of 96 nucleotides in length, much longer than the 15-mer above, of which 60 nucleotides are random sequences and 36 nucleotides are primer-binding sequences for PCR amplification.
- a plurality of aptamer clones having the above are isolated, and the above 15 mer are commonly present (or “conserved") among the plurality of thrombin-binding clones, and even if isolated, they are thrombin-bound. It was a core sequence that maintained its ability. Thus, it is typically seen in other nucleic acid aptamers that additional sequences may be present on the 5'and / or 3'side of the core sequence responsible for target binding.
- the linker can be bound to various sites of the thrombin-binding aptamer.
- a compound in which a linker is bound to the base of the 3-position T, the 9-position T, or the 12-position T of the above 15-mer is provided. Since the thrombin-binding aptamer is a DNA aptamer, it originally has a T base.
- the nucleic acid aptamer constituting a part of this compound is 5'-CAGCACCGACTTGTGCTTTGGGAGTGCTGGTCCAAAGGGCGTTAATGGACA-3' It is a SARS-CoV-2 spike protein binding aptamer having the sequence of (SEQ ID NO: 2). That is, a compound containing a nucleic acid aptamer having the sequence of SEQ ID NO: 2 and a fluorinated sulfonyl group linked to the nucleic acid aptamer via a linker, or a neutralizable covalent drug compound is provided.
- the nucleic acid aptamer itself is described in Song et al., Anal.
- SARS-CoV-2 is a new type of coronavirus that causes a pandemic as of 2020, and its spike protein binds to ACE2 receptors expressed on cells such as the human respiratory system and enters humans. It is a viral protein that mediates the initiation of infection.
- the DNA aptamer of SEQ ID NO: 2 was identified by Song et al. Based on the indicator that it binds to the receptor binding domain (RBD) of the spike protein and competes with ACE2 for binding to RBD. It is a thing. Further nucleic acid sequences may be added to the 5'and / or 3'sides of the above sequence.
- Embodiments of the above compounds or compositions comprising them are also contemplated for use in methods of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor in vitro or in vivo.
- Embodiments of a method of inhibiting the binding of SARS-CoV-2 to a subject's ACE2 receptor comprising administering to the subject an effective amount of the above compound or a composition comprising it are also contemplated.
- the linker can be bound to various sites of the nucleic acid aptamer.
- a compound in which a linker is bound to the base of the 12-position T, the 29-position T, or the 42-position T of the 51-mer of SEQ ID NO: 2 is provided.
- the nucleic acid aptamers constituting a portion of the compound are 5'-CAATTGGGCCCGTCCGTATGGGTGGGT-3' It is a VEGF binding aptamer having the sequence of (SEQ ID NO: 3). That is, a compound containing a nucleic acid aptamer having the sequence of SEQ ID NO: 3 and a fluorinated sulfonyl group linked to the nucleic acid aptamer via a linker, or a neutralizable covalent drug compound is provided.
- the nucleic acid aptamer itself is described in Kaur and Yung, PLoS ONE, 2021, 7: e31196.
- VEGF vascular endothelial growth factor
- This nucleic acid aptamer is made by Kaur et al. By truncating a longer existing VEGF binding aptamer and has a very high target binding affinity with a K d value of 0.5 ⁇ 0.32 nM. Further nucleic acid sequences may be added to the 5'and / or 3'sides of the above sequence.
- the linker can be bound to various sites of the nucleic acid aptamer.
- a compound in which a linker is bound to the base of the 4-position T, the 17-position T, or the 22-position T of the 26-mer of SEQ ID NO: 3 is provided.
- a pharmaceutical composition comprising any of the above-mentioned neutralizable covalent drug compounds.
- the present disclosure provides the neutralizable covalent drug compounds for use as pharmaceuticals.
- methods comprising administering to the subject the neutralizable covalent drug compound.
- the subject of administration or treatment in the present disclosure may be an animal, particularly a mammal.
- the subject may be human.
- the term "subject" may be used interchangeably with the term "patient”.
- the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier or excipient.
- a pharmaceutically acceptable carrier or excipient is water.
- routes of administration include, but are not limited to, oral, intravenous, arterial, intramuscular, subcutaneous, transdermal, intraperitoneal, intrathecal, transrectal, transvaginal, and inhalation.
- an anticoagulant comprising a neutralizable covalent drug compound comprising a nucleic acid aptamer having the sequence of SEQ ID NO: 1 and a fluorinated sulfonyl group linked to the nucleic acid aptamer via a linker.
- the present disclosure provides the neutralizable covalent drug compound for use as an anticoagulant.
- the anticoagulant referred to in the present disclosure is an agent that prevents or suppresses blood coagulation.
- Anticoagulants can also further include pharmaceutically acceptable carriers or excipients. A typical example of such a carrier or excipient is water.
- Anticoagulants can be found to be useful in all in vitro, ex vivo, and in vivo situations.
- the anticoagulant is provided with the anticoagulant or compound for use in a method of preventing or suppressing blood coagulation in a patient.
- the present disclosure also provides a method of preventing or suppressing blood coagulation in a patient, comprising administering to the patient an effective amount of the anticoagulant or compound.
- the anticoagulant can be administered to the patient, for example by intravenous administration, intraarterial administration, or oral administration. Patients are, for example, patients in need of long-term anticoagulant treatment.
- Patients are, for example, patients with thrombosis, deep vein thrombosis, vascular occlusion disease, thrombotic embolism, myocardial infarction, atrial fibrillation, stroke, systemic inflammatory disease (eg with COVID-19), or of these. Patients may be at risk of disease or have a need for prevention, but are not limited to these.
- the patient can also be a patient undergoing artificial blood vessel replacement.
- the patient may be a patient undergoing catheterization, prosthetic valve replacement, or coronary artery bypass grafting.
- the anticoagulant of this embodiment can be a substitute for heparin.
- the use of the anticoagulant of this embodiment may be beneficial because heparin may not be available in rare patients with heparin-induced thrombocytopenia and antithrombin deficiency.
- the method can include administering the anticoagulant to the patient and, after the administration of the anticoagulant, further administering an oligonucleotide complementary to the nucleic acid aptamer constituting the anticoagulant. ..
- an oligonucleotide complementary to a nucleic acid aptamer is an oligonucleotide capable of specifically hybridizing with the nucleic acid aptamer in physiological saline (0.9% w / v NaCl) at 37 ° C. could be.
- Complementary oligonucleotides can interfere with the aptamer-target interaction structure by specifically hybridizing with the nucleic acid aptamer and release the aptamer's specific binding to the target.
- Complementary oligonucleotides are sometimes referred to as "antidotes" in the context of nucleic acid aptamer-based drugs. Breaking a nucleic acid aptamer-based binding by its complementary oligonucleotide is an established technique (Rusconi et al., Nat Biotechnol, 2004, 22 (11), 1423-8; Stollet et al., Molecules, 2017. , 22 (6), 954; Bompiani et al., Curr Pharm Biotechnol, 2012, 13 (10), 1942-34; see also the example below). Specific sequences of suitable complementary oligonucleotides can be determined by one of ordinary skill in the art based on conventional knowledge.
- complementary oligonucleotides may be administered after sufficient efficacy of the anticoagulant has been obtained, or after adverse side effects or overeffects have begun to occur.
- the route of administration of the complementary oligonucleotide may be the same as the route of administration of the anticoagulant, or may be different from the route of administration of the anticoagulant.
- the type of complementary oligonucleotide in the present disclosure is not limited as long as the nucleic acid aptamer can hybridize to the complementary oligonucleotide, and may be the same as or different from the nucleic acid aptamer.
- the antidote to the DNA aptamer may be oligonucleotide RNA or oligonucleotide DNA.
- Complementary oligonucleotides in the present disclosure also include those containing one or more nucleic acid modifications or unnatural nucleic acid moieties known to those of skill in the art.
- the length of the complementary oligonucleotide is not particularly limited and can be appropriately determined by those skilled in the art, and may be, for example, 10 to 50 nucleotides (base) length.
- Complementary oligonucleotides can be, for example, oligonucleotides that are complementary over at least half the length of a nucleic acid aptamer.
- Complementary oligonucleotides are also referred to herein as complementary strands.
- the neutralizable covalent drug compound having a nucleic acid aptamer moiety and its complementary oligonucleotide can be provided as a combination or used as a combination.
- a neutralizable covalent drug comprising the above-mentioned compound, composition, or anticoagulant and an oligonucleotide complementary to the nucleic acid aptamer in the compound, composition, or anticoagulant.
- the system is provided. This system may be provided and / or used as a kit.
- the compound, composition, or anticoagulant and the complementary oligonucleotide are usually separate formulations that are administered separately, but the formulations may be provided in the same package or in separate packages. May be provided inside.
- the system or kit may further include instructions for explaining that the complementary oligonucleotide neutralizes the pharmaceutical action of the compound, composition, or anticoagulant.
- Instructions for use may, for example, be enclosed in the packaging of the compound, composition, or anticoagulant and / or complementary oligonucleotide, or may be printed on the packaging.
- the present disclosure is in another aspect.
- a method for producing a neutralizable covalent drug capable of forming a covalent bond with a target protein a) (a1) A nucleic acid aptamer specific to the target protein to which an alkynyl group, a cycloalkynyl group, or a heterocycloalkynyl group, or (a2) an azide group is linked or bound, and b) Warhead compounds having a structure in which the corresponding (b1) azido group, or (b2) alkynyl group, cycloalkynyl group, or heterocycloalkynyl group and fluorinated sulfonyl group are linked or bonded are reacted.
- this production method can produce the above-mentioned neutralizable covalent drug compound having a linker containing a linking moiety formed by an azido-alkyne click chemistry reaction.
- the structural and functional description provided herein for aspects of this process can also be applied to aspects of the above compounds and vice versa.
- the combination of the target protein and the specific nucleic acid aptamer for the target protein can be selected from those known to those skilled in the art.
- the method of the present embodiment can also be described as a method of covalently dragging a nucleic acid aptamer or a method of imparting covalent binding functionality to a nucleic acid aptamer.
- a group having an intercarbon triple bond (-C ⁇ C-) that can be used for an azido-alkyne click chemistry reaction including an alkynyl group, a cycloalkynyl group, and a heterocycloalkynyl group, is also referred to as an "alkyne structure”.
- the alkynyl group may be based on a terminal alkyne or an internal alkyne.
- a heterocycloalkynyl group is one in which one or more carbons in the ring of the cycloalkynyl group are replaced with a non-carbon atom such as nitrogen. Typically, the carbon of the part of the ring that binds to the linker can be replaced with nitrogen.
- Cycloalkynyl and heterocycloalkynyl groups can be used in the SPAAC described above, thus allowing the click chemistry reaction to occur in the absence of copper (I) ions.
- the azide group is a group represented by the formula -N 3 .
- alkyne structures known to those skilled in the art as those that can be used for SPAAC are OCT (cyclooctyne), MOFO (monofluorocyclooctyne), DIFO (difluorocyclooctyne), DIMAC (dimethoxyazacyclooctyne), DIFBO (difluorotin).
- OCT cyclooctyne
- MOFO monofluorocyclooctyne
- DIFO difluorocyclooctyne
- DIMAC diimethoxyazacyclooctyne
- DIFBO difluorotin
- a specific example of a heterocycloalkynyl group is shown in Chemical Formula III below, and a specific example of a cycloalkynyl group is shown in Chemical Formula IV below.
- the group (a1) or the group (a2) may be directly bound to the nucleic acid aptamer, or may be linked to the nucleic acid aptamer via a linker.
- cycloalkynyl groups, heterocycloalkynyl groups, and azide groups are typically linked to nucleic acid aptamers via a linker.
- the linker linking the nucleic acid aptamer and the group of the above (a1) or (a2) may be referred to as a first linker.
- the first linker is, for example, an alkylene having 1 to 10 carbon atoms, an alkenylene having 2 to 10 carbon atoms, an alkynylene having 2 to 10 carbon atoms, a heteroalkylene, a cycloalkylene, a heterocycloalkylene, an arylene, a heteroarylene, -CONH- ( Alternatively, it may be, but is not limited to, a divalent group comprising or consisting of -NHCO-), -CO-, -NH-, -O-, or a combination thereof.
- the above groups constituting the linker include substituted and unsubstituted ones.
- alkylene, arylene, heteroarylene, and / or -NH- hydrogen atoms can be substituted.
- typical substituents include, but are not limited to, alkyl and alkyloxy, aryl, hydroxyl, amino, halogen, and combinations thereof having 1 to 10 carbon atoms.
- Non-limiting specific examples of the first linker linking a nucleic acid aptamer (left) to an alkynyl group (right) are described below:-(CH 2 ) n- (n is an integer of 1 to 10); -O -CH 2 -;-(CH 2 ) n -NHCO- (CH 2 ) 2 -O-CH 2- (n is an integer of 1 to 10); -C ⁇ C- (CH 2 ) n- (n is 1) ⁇ 10 integers); and -C ⁇ C- (CH 2 CH 2 O) n- (CH 2 ) 2- (n is an integer of 1 to 10).
- a specific example of the first linker is -C ⁇ C- (CH 2 ) 4- .
- Non-limiting specific examples of the first linker linking a nucleic acid aptamer (left) to a cycloalkynyl group or a heterocycloalkynyl group (right) are described below:-(CH 2 CH 2 O) n- (CH 2 ).
- the group (b) corresponds to the group (a) above means that the azido-alkyne click chemistry reaction can be performed by the combination of the group (a) and the group (b).
- the group (a) is a group (a1) having an alkyne structure
- the group (b) is an azido group (b1)
- the group (a) is an azido group (a2).
- the group (b) becomes the group (b2) of the alkyne structure.
- Warhead compound is one of two compounds involved in the ligation reactions described herein, eg, the azido-alkyne click chemistry reaction, and is a fluoride that provides covalent bond-forming ability in covalent drugs. It means a compound having a sulfonyl group.
- the group (b1) or the group (b2) in the Warhead compound may be directly bonded to the fluorinated sulfonyl group, or may be linked to the fluorinated sulfonyl group via a linker.
- the linker linking the fluorinated sulfonyl group and the above-mentioned (b1) or (b2) group may be referred to as a second linker.
- the second linker is, for example, an alkylene having 1 to 10 carbon atoms, an alkenylene having 2 to 10 carbon atoms, an alkynylene having 2 to 10 carbon atoms, a heteroalkylene, a cycloalkylene, a heterocycloalkylene, an arylene, a heteroarylene, and -CONH- (.
- the terminal portion of the second linker that binds to the fluorinated sulfonyl group is arylene (for example, p-phenylene) or heterocycloalkylene (for example, 1,4-piperazinylene).
- the terminal portion of the second linker that binds to the fluorinated sulfonyl group is arylene, and the arylene can be provided as the above-mentioned carbonylphenylene.
- the second linker may be the acetyl-benzene moiety.
- the above groups constituting the linker include substituted and unsubstituted ones.
- alkylene, arylene, heteroarylene, and / or -NH- hydrogen atoms can be substituted.
- typical substituents include, but are not limited to, alkyl and alkyloxy, aryl, hydroxyl, amino, halogen, and combinations thereof having 1 to 10 carbon atoms.
- a specific example of the second linker is -CH 2 -CO-C 6 H 4- .
- Warhead compound Non-limiting specific examples of the Warhead compound are shown in the following chemical formulas (V) to (X).
- the portion connecting the azide group and the fluorinated sulfonyl group is the second linker.
- All of the following compounds have an azido group, but warhead compounds having a (b2) group, i.e. an alkynyl group, a cycloalkynyl group, or a heterocycloalkynyl group, or another reactive group instead of the azido group are also contemplated.
- a (b2) group i.e. an alkynyl group, a cycloalkynyl group, or a heterocycloalkynyl group, or another reactive group instead of the azido group are also contemplated.
- the Warhead compound has the following structure:
- Z can be an azide group or an alkynyl group, a cycloalkynyl group, or a heterocycloalkynyl group or another reactive group.
- the click chemistry reaction between the azide and the alkyne forms the above-mentioned connecting portion derived from the alkyne structure and the azido group.
- the result is a structure in which the nucleic acid aptamer and the fluorinated sulfonyl group are linked via a linker containing this linking moiety (referred to as a "third linker" in the present disclosure).
- This structure can provide an embodiment of a neutralizable covalent drug compound and can also provide an active ingredient of a neutralizable covalent drug.
- the third linker can be a divalent group having a structure of-(first linker)-(the linking portion)-(second linker)-.
- the method may further include chemically synthesizing the nucleic acid aptamer of a) prior to performing the azido-alkyne click chemistry reaction.
- the nucleic acid aptamer component of a) in the present embodiment is essentially a modified nucleotide and can be synthesized by applying a known oligonucleotide chemical synthesis method.
- An example of a suitable chemical synthesis method is, but is not limited to, the phosphoramidite method.
- nucleoside having a nucleobase ligated or linked to the group (a1) or (a2) above can be used as a substrate at the desired residue of the desired sequence for oligo.
- nucleic acid aptamers to which the groups (a1) or (a2) are linked or linked can be chemically synthesized.
- Nucleic acid aptamers have the advantages of being able to provide high target specificity, being able to detoxify, and causing almost no immune response by themselves, so they can have high efficacy and safety, and are promising as pharmaceuticals. ing.
- low stability in vivo more specifically, short half-life in circulation due to removal in the kidney is considered to be a weakness of aptamer-type drugs, and its medical treatment. This is one of the reasons why the application is delayed.
- the aptamer-type covalent drug provided in the embodiments of the present disclosure is retained on or near the target protein once the warhead moiety forms a covalent bond with the target protein after binding to the target protein. , Can continue to maintain its effect on the target protein.
- an aptamer-type covalent drug can obtain a sustained efficacy in a pharmacokinetics different from that of a conventional aptamer-type drug having a passive and short half-life, and can neutralize the efficacy at a desired time. It is possible.
- thrombin-binding aptamer consisting of sequence 5'-GGT 3 TGGTGT 9 GGT 12 TGG-3'(SEQ ID NO: 1) described in Bock et al., Nature, 1992, 355, 564-566 (SEQ ID NO: 1).
- TBA thrombin binding aptamer
- alkyne linker-modified TBA consisting of a sequence in which the 3-position T, 9-position T, or 12-position T of the above sequence is replaced with an alkyne linker-modified T, respectively, integrated. Custom synthesized by DNA Technologies.
- alkyne linker-modified Ts are obtained by binding -C ⁇ C- (CH 2 ) 4 -C ⁇ CH to the 5-position of the pyrimidine ring of the thymine (T) base instead of the usual methyl group.
- -C ⁇ C- (CH 2 ) 4- can be recognized as the first linker and -C ⁇ CH as the alkynyl group.
- the corresponding thiol linker-modified TBA was custom synthesized.
- an unmodified VEGF-binding aptamer consisting of the sequence 5'-CAAT 4 TGGGCCCGTCCGT 17 ATGGT 22 GGGT-3' (SEQ ID NO: 3) described in Kaur and Yung, PLoS ONE, 2021, 7: e31196
- three types of alkyne linker-modified aptamers consisting of a sequence in which the 4-position T, 17-position T, or 22-position T of the above sequence was replaced with an alkyne linker-modified T were synthesized.
- Human ⁇ -thrombin was purchased from Haematologic Technologies of the United States (# HCT-0020), fibrinogen derived from human plasma was purchased from Aldrich of the United States (# 9001-32-5), and human serum was purchased from Aldrich of the United States (# H4522). ..
- the SARS-CoV-2 spike protein RBD (# SPD-C52H3) was purchased from ACRO Biosystems, USA.
- the synthesized Warhead compound was identified by NMR, and the ligation to the aptamer was confirmed by HPLC.
- the NMR experiment was performed at 25 ° C. using a 500 MHz nuclear magnetic resonance apparatus (JNM-ECA500, JEOL Ltd.).
- HPLC High Performance Liquid Chromatography
- analysis is connected to an optical diode array (PDA) and / or LCQ-Fleet ion trap mass spectrometer with a C18 reverse phase column (Hypersil GOLD, 2.1 x 100 mm, Thermo Fisher Scientific, USA).
- a 0-100% acetonitrile gradient containing 0.1% formic acid was performed at a flow rate of 300 ⁇ L / min.
- a small-scale quantitative analysis of the aptamer was performed using a fluorescence detector followed by a reverse phase semi-micro HPLC system (PU-2085 with C18 column, JASCO Corporation) connected to the PDA.
- Aptamers were separated by using a 0-60% acetonitrile gradient containing 20 mM triethylamine acetate aqueous solution (pH 7.4) at a flow rate of 200 ⁇ L / min for 26 minutes.
- CD (circular dichroism) spectra of unmodified TBA, alkyne linker-modified TBA (T 3 ), and Warhead-conjugated TBA (TBA 3 ) were measured.
- TBA 3 alkyne linker-modified TBA
- TBA 3 Warhead-conjugated TBA
- 10 ⁇ M aptamers were kept in D-PBS (pH 7.4) at 37 ° C. and the spectra from 220 to 340 nm were scanned at 100 nm / min (J-720W Circular Dichroism Dispersometer, JASCO Corporation). Company). The average of the triple measurements was taken and plotted.
- the CD spectrum of unmodified TBA is consistent with previous reports (Nagatoishi et al., Biochem. Biophys. Res. Commun., 2007, 352, 812-817), indicating the presence of G-quadruplex structure in solution. It was shown (Fig. 3a).
- Warhead compound 1 was synthesized on a preparation scale by the following procedure. 4- (2-bromoacetyl) -benzene-1-sulfonylfluoride (71.1 ⁇ mol, Aldrich, USA, # 00364) and sodium azide (64.6 ⁇ mol, Wako Pure Chemical Industries, Ltd., # 195-1092) in 323 ⁇ L of dimethyl sulfoxide. Mixed in (DMSO). The reaction mixture was vortexed at room temperature for 10 minutes, then mixed with cold water (0.5 mL) and extracted with ethyl acetate (1 mL).
- Warhead compound 1 shown on the right side of the above figure was identified by 1 H and 13 C NMR. In the compound, the acetyl-benzene moiety can be recognized as a second linker.
- the crude reaction product was cooled to 3M sodium acetate (9 ⁇ mol in water) and -20 ° C. Ethanol was added and incubated at -20 ° C for 1 hour. Then centrifugation was performed (15000 rpm, 20 minutes, 4 ° C), the supernatant was removed, and the precipitate was washed with a 70% ethanol solution and then nuclease-free water. A pure aptamer to which each warhead was linked was identified by HPLC analysis.
- the Warhead compound 4- (2-bromoacetyl) -benzene-1-sulfonylfluoride or ethensulfonylfluoride was reacted with the thiol group and thioether-linked under the following conditions: A mixture of 50 ⁇ M thiol linker-modified aptamer, TCEP 2.5 mM, and 10 mM warhead compound in 100 mM Tris-HCl pH 8.8 was reacted at 4 ° C for 3 hours, and then the warhead-modified aptamer was recovered by ethanol precipitation.
- Warhead (BSF) in the form of carbonyl-benzene-sulfonyl fluoride
- BSF linkage of Warhead
- ESF ethyl-sulfonyl fluoride
- TBA 3 , TBA 9 , and TBA 12 Covalent mobility shift assay Unmodified TBA and TBA (referred to as TBA 3 , TBA 9 , and TBA 12 ) (100 ⁇ M each) with a warhead ligated to any of the above three sites of the nucleic acid sequence, respectively, are phosphate buffered. It was mixed with trombin (25 ⁇ M) in saline (PBS, pH 7.4) and incubated at 37 ° C. for 12 hours. The mixture was then mixed with 1X sample buffer and separated by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
- thrombin inhibitory activity 4.1. Evaluation of Thrombin Inhibitory Activity by Turbidimetry Assays Different molar concentrations of unmodified TBA or TBA 3 in PBS (pH 7.4) were mixed with constant concentrations of thrombin (25 ⁇ M) and incubated at 37 ° C. for 3 hours. Then each reaction mixture is added to a solution of fibrinogen in PBS (pH 7.4) to a final concentration of 2.5 nM thrombin and 1 mg / mL fibrinogen, using a 10-mm plastic cell NanoPhotometer TM (Implen, Germany). The absorbance of the polymerized fibrin at the maximum absorption wavelength (288 nm) was measured every 10 seconds. In each experiment, the absorbance at 0 seconds was standardized as 0 and the relative absorbance at each of the other time points was determined.
- Thrombin 25 ⁇ M was treated in PBS (pH 7.4) with or without TBA 3 (100 ⁇ M) and incubated at 37 ° C. for 3 hours. Experiments were also performed in which this treatment was performed in the presence of 40% (v / v) human serum to confirm binding specificity. The mixture was subsequently treated at 37 ° C. for 30 minutes with or without FAM-labeled complementary strand (400 ⁇ M). Each sample was mixed with 1X sample buffer, separated by 12.5% SDS-PAGE and analyzed by in-gel fluorescence imaging. All proteins were visualized by CBB staining.
- Table 1 shows the addition concentrations of aptamer and complementary chain antidote, except that the final concentrations of 13 nM thrombin and 2 mg / mL fibrinogen were set to 5.2 above. .. Mixing was performed in the same manner as above. The change in coagulation time was measured with a BFT II analyzer.
- FIG. 1 shows the results of HPLC analysis of the reaction mixture after undergoing a reaction in which a sulfonyl fluoride group (warhead) is ligated to a nucleic acid aptamer.
- the unreacted product that is, the peak corresponding to the aptamer to which the alkynyl group is linked but the fluorinated sulfonyl group is not linked is surrounded by a frame.
- the large peak seen to the right of the frame corresponds to the reactant, the aptamer to which the fluorinated sulfonyl group is further linked. It can be seen that at any of the sites tested for thrombin-bound aptamers (TBA), a warhead introduction efficiency of 90% or higher was obtained without purification.
- TAA thrombin-bound aptamers
- FIG. 2 (a) shows unmodified TBA, or TBA linked with a fluorinated sulfonyl group via an azido-alkyne click chemistry, incubated with thrombin at 37 ° C. for 12 hours, and then the reaction mixture is SDS. -The results of separation by PAGE and visualization of proteins by CBB are shown.
- the first lane of the gel shown is a molecular weight marker.
- Thrombin alone has a molecular weight of about 36 kDa (second lane). Even if unmodified TBA is bound to this, thrombin mobility does not change when it is allowed to flow through SDS-PAGE gel, which is a reduction / denaturation condition (lane 3).
- TBAs (TBA 3 , TBA 12 , and TBA 9 , respectively) linked to a fluorinated sulfonyl group via a linker were attached to positions 3, 12, or 9 of the nucleic acid sequence.
- aptamers formed covalent bonds to thrombin, thus confirming a shift in thrombin mobility, i.e., an increase in molecular weight, on SDS-PAGE (lanes 4-6, "thrombin-TBA").
- the covalently bound thrombin band was excised from the gel and mass spectrometrically analyzed for tryptic digested peptide fragments.
- the peptide IYIHPR was identified as at least one covalent bond position (data not shown).
- FIG. 2 (a) show that more or less covalent bonds could be formed by varying the mounting location of the warhead.
- Nucleic acid aptamers do not function as genetic material, but as binding objects that provide a large number of interaction points as a whole.
- the warhead is linked to the thymine base, but it is not necessary to use thymine, and it is understood that the warhead can be linked to other bases or nucleic acid terminals.
- TBA's T 3 and T 12 are located approximately on the thrombin junction, while T 9 is far from the thrombin junction.
- TBA 9 has a lower covalent bond formation rate than TBA 3 and TBA 12 (lane 6) is consistent with that speculation.
- FIG. 2 (a) the presence of a band corresponding to thrombin in which two molecules of aptamers were covalently bonded was also observed (“thrombin-TBA ⁇ 2”).
- thrombin-TBA ⁇ 2 the non-covalent bond of the aptamer moiety dissociates once, and the second aptamer molecule is in the gap. It suggests that it bound to the same trombine molecule to form a covalent bond.
- Once dissociated like this first aptamer molecule, it may be removed by the bloodstream, but if it has a covalent bond, it stays in the vicinity of the target and has an opportunity for recombination. May have.
- the same thiol linker as in non-patent document 4 is bonded to the T 3 position of TBA, and the same alkyl type ESF warhead thioether bond (thio) as in non-patent document 4 is attached thereto.
- the resulting warhead-modified aptamers were unable to generate any covalent bonds to the aptamer target.
- the second lane from the right in FIG. 2 (c) is the same ESF warhead connected to the T3 position of TBA via the azide - alkyne click chemistry (click).
- Aryl-type BSF warheads (rightmost lane in FIG.
- FIG. 2c and FIG. 2a gave clear covalent bonds, albeit not at the same level.
- the remarkable superiority of aryl-type warheads in the context of aptamer-type covalent agents was also revealed.
- the second lane from the right in FIG. 2 (b) relating to the thioether linkage has a detectable covalent bond formation unlike the rightmost lane
- FIG. 2 (c) relating to the azido-alkyne click chemistry linkage can be recognized in the comparison of the first and second lanes from the right.
- the results in FIG. 2 show the importance of the use of azido-alkyne click chemistry linkages and / or the use of aryl-type warheads in aptamer-type covalent agents.
- Warhead-modified TBA and unmodified TBA have similar binding sites on the target.
- the results in FIG. 3 show that the aptamer's original fundamental properties are largely or completely unaffected by the Warhead coupling.
- FIG. 4A is data showing the concentration dependence in the covalent bond formation reaction by Warhead-modified TBA.
- FIG. 4 (b) the intensity of the unreacted thrombin band that did not form a covalent bond was quantified on the SDS-PAGE gel.
- Warhead-modified TBA was able to recognize thrombin and rapidly form covalent bonds at human body temperature (37 ° C.).
- a Warhead-modified aptamer makes a specific non-covalent bond to a target protein, a nucleophilic amino acid on the target protein located in the vicinity of the fluorinated sulfonyl group reacts with the fluorinated sulfonyl group to form a covalent bond. I can think of it.
- Warhead-modified TBA and thrombin were mixed in the presence of serum protein. After that, a FAM-modified complementary strand was also added. A photograph of in-gel fluorescence imaging in which fluorescence derived from FAM was detected is shown on the right side of the photograph of CBB staining. Despite the presence of large amounts of serum protein, only thrombin was covalently bound to Warhead-modified TBA to cause a mobility shift, and only the thrombin molecule that caused the mobility shift became a FAM-modified complementary strand. It can be confirmed that they are combined. These data show the high specificity of each of the Warhead modified aptamers and complementary strands.
- Thrombin is a serine protease enzyme that cleaves fibrinogen to produce fibrin, and this fibrin is polymerized to form polymerized fibrin. Polymerized fibrin can be quantified by measuring the absorbance at 288 nm in a turbidimetric assay.
- the inhibition of thrombin activity by TBA was investigated using the activity of producing polymerized fibrin from fibrinogen as an index.
- TBA 3 had a significantly enhanced thrombin inhibitory ability as compared with unmodified TBA.
- Warhead-modified TBA 3 (Fig. 6c) had about 3.5 times the inhibitory activity as compared with unmodified TBA (Fig. 6b). That is, Warhead-modified TBA 3 was able to inhibit thrombin activity at lower concentrations.
- Warhead-modified TBA prolonged the coagulation time by about 2 times at low concentration (1 nM) and about 5 times or more at high concentration (5 nM) (Table 1). Unmodified TBA was also able to extend the coagulation time to 200 seconds or more when added at a high concentration of 100 nM (not shown in the table).
- FIG. 7 (a) shows a Warhead-modified aptamer in which a fluorinated sulfonyl group is linked to the 12-position T base of the SARS-CoV-2 spike protein-binding aptamer of SEQ ID NO: 2, and the SARS-CoV-2 spike.
- the results of a mobility shift assay using SDS-PAGE as described above after incubating with the receptor binding domain (RBD) of the protein at 37 ° C for 12 hours are shown.
- RBD is a protein domain responsible for viral binding to human host cells, and the aptamer can inhibit RBD from binding to human receptors (Song et al.). Warhead-modified aptamers covalently reacted with RBD to cause a mobility shift on SDS-PAGE (Fig. 7a left). The right side of FIG. 7a shows the result of quantifying the proportion of unreacted RBD bands that do not form covalent bonds (that is, are not shifted). Similar results were obtained by linking fluorinated sulfonyl groups to different locations in the aptamer (Fig. 7b).
- FIG. 7 (c) shows the results of a similar mobility shift assay performed by mixing VEGF with a Warhead-modified aptamer in which a fluorinated sulfonyl group is linked to different sites of a VEGF-bound aptamer. Both warhead-modified aptamers covalently reacted with VEGF to cause a mobility shift on SDS-PAGE.
- aptamer-type drugs In addition to high target specificity, the ability to detoxify with complementary strands is also a feature of aptamer-type drugs.
- the latter part of FIG. 8 and Table 1 is data confirming that this characteristic of the aptamer is maintained even with the connection and covalent bond formation of the warhead.
- 1.2 nM Warhead-modified thrombin-bound aptamer (TBA 3 ) was incubated with thrombin at 37 ° C, then added with different concentrations of complementary strands for further incubation, followed by fibrinogen to accumulate polymerized fibrin (Fig. 8).
- fibrinogen fibrinogen to accumulate polymerized fibrin
- thrombin activity was measured based on the time required for coagulation (Table 1).
- Thrombin inhibition by Warhead-modified TBA 3 was neutralized in a concentration-dependent manner by the complementary strand, and thrombin activity was restored to a state of almost no inhibition when 16 nM complementary strand was added (Fig. 8a). ..
- the EC50 of the complementary strand was calculated to be 4.6 ⁇ 0.3 nM in this experimental system (Fig. 8b).
- Fig. 8b Experiments with the corresponding unmodified TBA yielded an EC 50 of 2.3 ⁇ 0.2 nM, with unmodified TBA appearing to be slightly more sensitive to complementary strands (not shown), but covalent. It was clear from the results of FIG. 8 that the effect of the bound Warhead-modified TBA could be neutralized by the complementary strand.
- Table 1 for coagulation time also clearly support that administration of complementary strands can neutralize the effects of aptamers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
[1]
核酸アプタマーと、前記核酸アプタマーにアジド-アルキン間クリックケミストリー反応を介して連結されたフッ化スルホニル基とを含む、中和可能コバレントドラッグ化合物であって、
前記アプタマーと前記フッ化スルホニル基とが、前記アジド-アルキン間クリックケミストリー反応により形成される連結部分を含むリンカーによって連結されている、
中和可能コバレントドラッグ化合物。
[2]
前記リンカーが、-L1-Y-L2-という式で表わされ、ここで、Yは、前記アジド-アルキン間クリックケミストリー反応により形成される連結部分であり、L1は前記核酸アプタマーに結合する第1のリンカー部分であり、L2は前記フッ化スルホニル基に結合する第2のリンカー部分であり、
前記第2のリンカー部分のうち前記フッ化スルホニル基に結合する末端部分がアリーレンである、[1]に記載の中和可能コバレントドラッグ化合物。
[3]
前記フッ化スルホニル基に結合する末端部分のアリーレンが下記構造中に提供されている、
[2]に記載の中和可能コバレントドラッグ化合物。
[4]
前記リンカーは、前記核酸アプタマー中の核酸塩基に結合している、[1]~[3]のいずれか一項に記載の中和可能コバレントドラッグ化合物。
[5]
前記核酸アプタマーが、
5’-GGTTGGTGTGGTTGG-3’
の配列(配列番号1)を有するトロンビン結合アプタマーである、[1]~[4]のいずれか一項に記載の中和可能コバレントドラッグ化合物。
[6]
[1]~[5]のいずれか一項に記載の中和可能コバレントドラッグ化合物を含む医薬組成物。
[7]
[5]に記載の中和可能コバレントドラッグ化合物を含む抗凝固剤。
[8]
患者における血液凝固を防止または抑制する方法における使用のための、[7]に記載の抗凝固剤であって、前記方法は、前記患者に前記抗凝固剤を投与すること、および、前記抗凝固剤の投与後に、前記核酸アプタマーに対して相補的なオリゴヌクレオチドをさらに投与することを含む、抗凝固剤。
[9]
[1]~[5]のいずれか一項に記載の化合物、[6]に記載の組成物、または[7]もしくは[8]に記載の抗凝固剤と、
前記核酸アプタマーに対して相補的なオリゴヌクレオチドと
を含む、
中和可能コバレントドラッグシステム。
[10]
標的蛋白質に対して共有結合を形成することができる中和可能コバレントドラッグの製造方法であって、
a)(a1)アルキニル基、シクロアルキニル基、もしくはヘテロシクロアルキニル基、または(a2)アジド基が連結または結合された、標的蛋白質に特異的な核酸アプタマー、および、
b)対応する(b1)アジド基、または(b2)アルキニル基、シクロアルキニル基、もしくはヘテロシクロアルキニル基とフッ化スルホニル基とが連結または結合された構造を有する、ウォーヘッド化合物
を反応させて、アジド-アルキン間クリックケミストリー反応を行い、前記アジド-アルキン間クリックケミストリー反応により形成された連結部分を含むリンカーを介して前記核酸アプタマーと前記フッ化スルホニル基とが連結された構造を取得することを含む、方法。
[11]
前記ウォーヘッド化合物は、前記フッ化スルホニル基と前記アジド基またはアルキニル基、シクロアルキニル基、もしくはヘテロシクロアルキニル基とを連結する第2のリンカーを含み、
前記第2のリンカーのうち前記フッ化スルホニル基に結合する末端部分がアリーレンである、
[10]に記載の方法。
[12]
前記フッ化スルホニル基に結合する末端部分のアリーレンが下記構造中に提供されている、
[11]に記載の方法。
[13]
核酸アプタマーと、前記核酸アプタマーにリンカーを介して連結されたフッ化スルホニル基とを含み、前記リンカーのうち前記フッ化スルホニル基に結合する末端部分がアリーレンである、中和可能コバレントドラッグ化合物。
[14]
前記フッ化スルホニル基に結合する末端部分のアリーレンが下記構造中に提供されている、
[13]に記載の中和可能コバレントドラッグ化合物。
これは銅(I)触媒アジド-アルキン環化付加(CuAAC)と呼ばれるアジド-アルキン間クリックケミストリー反応により形成される連結部分である。上記で示す構造式の左側(左腕)が核酸アプタマーに連結または結合され右側(右腕)がフッ化スルホニル基に連結または結合される態様が好ましいが、その逆であってもよい。
例えば、L2(第2のリンカー部分)がアセチル-ベンゼン部分すなわちメチレン-カルボニル-フェニレンであってもよい。
5’-GGTTGGTGTGGTTGG-3’
の配列(配列番号1)を有するトロンビン結合アプタマーである。すなわち、配列番号1の配列を有する核酸アプタマーと、その核酸アプタマーにリンカーを介して連結されたフッ化スルホニル基とを含む化合物あるいは中和可能コバレントドラッグ化合物が提供される。トロンビンは、フィブリノゲンを切断してフィブリンを産生することにより、血液の凝固に関わる酵素である。このトロンビン結合核酸アプタマー自体は、Bock et al., Nature, 1992, 355, 564-566に記述されている。上記配列の5’側および/または3’側にさらなる核酸配列が追加されていてもよい。実際、Bock et al.は、上記15マーよりはるかに長い96ヌクレオチド長(そのうち60ヌクレオチドがランダム配列であり36ヌクレオチドがPCR増幅用のプライマー結合配列である)の核酸集団からのスクリーニングでトロンビン結合能を有するアプタマークローンを複数単離したのであり、上記15マーは、それら複数のトロンビン結合クローン間に共通して存在しており(あるいは、「保存」されており)かつ単離されてもトロンビン結合能を維持するコア配列であった。このように、標的結合能を担うコア配列の5’側および/または3’側に追加的配列が存在し得ることは他の核酸アプタマーにおいても典型的に見られる。
5’-CAGCACCGACCTTGTGCTTTGGGAGTGCTGGTCCAAGGGCGTTAATGGACA-3’
の配列(配列番号2)を有するSARS-CoV-2スパイクタンパク質結合アプタマーである。すなわち、配列番号2の配列を有する核酸アプタマーと、その核酸アプタマーにリンカーを介して連結されたフッ化スルホニル基とを含む化合物あるいは中和可能コバレントドラッグ化合物が提供される。この核酸アプタマー自体は、Song et al., Anal. Chem., 2020, 92, 9895-9900に記述されている。SARS-CoV-2は、2020年の時点でパンデミックを引き起こしている新型コロナウイルスであり、そのスパイクタンパク質は、ヒトの呼吸器系等の細胞上に発現されるACE2受容体に結合してヒトへの感染開始を媒介するウイルスタンパク質である。配列番号2のDNAアプタマーは、スパイクタンパク質の受容体結合ドメイン(receptor binding domain:RBD)に結合すること、およびRBDへの結合についてACE2と競合することという指標に基づいてSong et al.によって同定されたものである。上記配列の5’側および/または3’側にさらなる核酸配列が追加されていてもよい。インビトロまたはインビボでACE2受容体へのSARS-CoV-2の結合を阻害する方法における使用ための上記化合物またはそれを含む組成物の実施形態も企図される。対象のACE2受容体へのSARS-CoV-2の結合を阻害する方法であって、対象に有効量の上記化合物またはそれを含む組成物を投与することを含む方法の実施形態も企図される。
5’-CAATTGGGCCCGTCCGTATGGTGGGT-3’
の配列(配列番号3)を有するVEGF結合アプタマーである。すなわち、配列番号3の配列を有する核酸アプタマーと、その核酸アプタマーにリンカーを介して連結されたフッ化スルホニル基とを含む化合物あるいは中和可能コバレントドラッグ化合物が提供される。この核酸アプタマー自体は、Kaur and Yung, PLoS ONE, 2021, 7:e31196に記述されている。VEGF(vascular endothelial growth factor:血管内皮細胞増殖因子)は、広く癌細胞で過剰発現される強力な血管新生性の***促進因子である。この核酸アプタマーは、より長い既存のVEGF結合アプタマーを切り詰めることによってKaurらによって作られた、Kd値0.5±0.32nMというきわめて高い標的結合親和性を有するものである。上記配列の5’側および/または3’側にさらなる核酸配列が追加されていてもよい。
標的蛋白質に対して共有結合を形成することができる中和可能コバレントドラッグの製造方法であって、
a)(a1)アルキニル基、シクロアルキニル基、もしくはヘテロシクロアルキニル基、または(a2)アジド基が連結または結合された、標的蛋白質に特異的な核酸アプタマー、および、
b)対応する(b1)アジド基、または(b2)アルキニル基、シクロアルキニル基、もしくはヘテロシクロアルキニル基とフッ化スルホニル基とが連結または結合された構造を有する、ウォーヘッド化合物
を反応させて、アジド-アルキン間クリックケミストリー反応を行い、該アジド-アルキン間クリックケミストリー反応により形成された連結部分を含むリンカーを介して上記核酸アプタマーと上記フッ化スルホニル基とが連結された構造を取得することを含む、方法を提供する。
1.全般的事項
Bock et al., Nature, 1992, 355, 564-566に記載された、配列5’-GGT3TGGTGT9GGT12TGG-3’(配列番号1)からなる無修飾のトロンビン結合アプタマー(TBA:thrombin binding aptamer)、および、上記配列の第3位T、第9位T、または第12位Tがそれぞれアルキンリンカー修飾Tで置き換えられた配列からなる3種類のアルキンリンカー修飾TBAを、Integrated DNA Technologies社においてカスタム合成した。これらのアルキンリンカー修飾Tは、チミン(T)塩基のピリミジン環の5位に、通常のメチル基の代わりに、-C≡C-(CH2)4-C≡CHが結合したものである。ここで、-C≡C-(CH2)4-を第1のリンカー、-C≡CHをアルキニル基として認識することができる。同様に、対応するチオールリンカー修飾TBAもカスタム合成した。チオールリンカー修飾Tは、チミン(T)塩基のピリミジン環の5位に、-CH=CH-CONH-(CH2)6-NHCO-(CH2)2-SHが結合したものである。
2.1.ウォーヘッド化合物1の合成
以下の手順により、ウォーヘッド化合物1を調製規模で合成した。
4-(2-ブロモアセチル)-ベンゼン-1-スルホニルフルオリド(71.1μmol、米国Aldrich社、#00364)とアジ化ナトリウム(64.6μmol、和光純薬、#195-11092)を、323μLのジメチルスルホキシド(DMSO)中で混合した。反応混合物を室温で10分間ボルテックスし、続いて冷水(0.5 mL)と混合して、酢酸エチル(1 mL)で抽出した。回収した有機相を飽和NaHCO3(0.5 mL×2)および鹹水(0.5 mL×2)で洗浄し、Na2SO4上で乾燥させ、蒸発させて、黄色固形物として純粋な産物を得た(11.8 mg、収率49%)。1Hおよび13C NMRによって、上図右側に示すウォーヘッド化合物1が同定された。該化合物において、アセチル-ベンゼン部分を第2のリンカーとして認識することができる。
トリス(3-ヒドロキシプロピルトリアゾリルメチル(水中に0.5μmol、米国Aldrich社、#762342)と硫酸銅(II) (水中に0.25μmol、米国Aldrich社、#451657)を混合した。次に、各アルキンリンカー修飾アプタマー(水中に10 nmol)と50 mMウォーヘッド化合物1(DMSO中に0.5μmol)を加え、さらにアスコルビン酸(水中に0.4μmol、米国Aldrich社、# A92902)を添加した後1時間にわたり室温で混合物を反応させた。反応産物を、エタノール沈殿により精製した。具体的には、粗製反応産物に3M酢酸ナトリウム(水中に9μmol)および-20℃に冷却したエタノールを加え、-20℃で1時間インキュベートした。その後遠心分離を行い(15000 rpm、20分、4℃)、上清を除去し、沈殿物を70%エタノール溶液で洗浄した後にヌクレアーゼフリー水に溶解した。HPLC分析により、それぞれウォーヘッドが連結された純粋なアプタマーが同定された。
3.1.共有結合モビリティシフトアッセイ
無修飾TBA、ならびに核酸配列の上記3箇所のいずれかにウォーヘッドが連結されたTBA(TBA3、TBA9、およびTBA12と呼ぶ)(各100μM)を、それぞれリン酸緩衝食塩水(PBS、pH 7.4)中でトロンビン(25μM)と混合し、37℃で12時間インキュベートした。その後混合物を1Xサンプルバッファーと混ぜ、12.5%ドデシル硫酸ナトリウム・ポリアクリルアミドゲル電気泳動(SDS-PAGE)により分離した。ゲル上の全蛋白質をクーマシーブリリアントブルー(CBB)染色により可視化した。TBAがトロンビンに共有結合すると、ゲル上でトロンビンのモビリティシフトとして検出することができた。ここではトロンビン結合アプタマーに関する代表的実験について説明しているが、SARS-CoV-2スパイクタンパク質結合アプタマーおよびVEGF結合アプタマーについても本質的に同じ実験手順が用いられた。
PBS(pH7.4)中でTBA3(100μM)とトロンビン(25μM)を混合して37℃で3時間インキュベートした。上記と同様にSDS-PAGE ゲルのCBB染色により蛋白質を可視化した。TBAが共有結合したトロンビンに相当する染色バンドをゲルから切り出した。ゲル中の蛋白質を65℃で10分間、25 mMジチオスレイトールで還元し、続いて室温、暗所で1時間にわたりヨードアセトアミドを用いてアルキル化した。消化は、25 mMのn-オクチル-ベータ-D-チオグルコシド(和光純薬、#349-05361)の存在下で修飾トリプシン(米国Promega社、#V5111)を用いて37℃で12時間にわたり行った。得られたペプチドを、LC-MS/PDAシステムを用いて分析した。トリプシン消化ペプチドは、0.1%ギ酸を含むアセトニトリル0%-50%勾配を用いて、流速300μL/分で55分間にわたって分離され、それから溶出したペプチドが質量分析計に直接スプレーされた。質量分析計はデータ依存モードで操作し外部較正した。サーヴェイMSスキャンを200-2000 m/zレンジで取得した。スキャンごとに、高強度の複数荷電イオンをイオントラップ中で衝突誘起解離によって断片化した。動的排除ウィンドウを30秒間以内で適用した。全てのタンデム質量スペクトルは40 %の標準化衝突エネルギーを用いて収集された。Xcaliburソフトウェアv.2.07(米国Thermo Scientific社)を用いてデータを取得し分析した。
4.1.比濁法アッセイによるトロンビン阻害活性の評価
PBS(pH 7.4)中で異なるモル濃度の無修飾TBAまたはTBA3を定濃度のトロンビン(25μM)と混合し、37℃で3時間インキュベートした。その後、各反応混合物をフィブリノゲンのPBS(pH 7.4)溶液に加えて、2.5 nMトロンビンおよび1 mg/mLフィブリノゲンの最終濃度とし、10-mmプラスチックセルを用いてNanoPhotometer(商標)(ドイツ国Implen社)により10秒ごとに、重合フィブリンの最大吸収波長(288 nm)における吸光度を測定した。各実験において、0秒の時点における吸光度を0として標準化し、他の各時点における相対的吸光度を決定した。
13 nMトロンビンおよび2 mg/mLフィブリノゲンの最終濃度としたことを除き上記4.1.と同じように混合を行った。凝固自動測定装置であるBFT IIアナライザー(ドイツ国SIEMENS Healthineers社)により凝固時間の変化を測定した。
5.1.相補鎖解毒剤の結合
TBAに対する相補鎖(すなわち解毒剤)DNAオリゴヌクレオチドの配列は5’-CCAACCACACCAACC-3’(配列番号4)であった。また、5’末端をフルオレセインで標識した同じ相補鎖も合成した(FAM修飾相補鎖という)。
PBS(pH 7.4)中で無修飾TBA(3.5 nM)またはTBA3(1.2 nM)をトロンビン(25μM)と混合し、37℃で3時間インキュベートした。次に各反応混合物に、異なる濃度の相補鎖解毒剤を加え、37℃で30分間インキュベートした。それから、各反応混合物をフィブリノゲンのPBS(pH 7.4)溶液に加えて、2.5 nMトロンビンおよび1 mg/mLフィブリノゲンの最終濃度とし、10-mmプラスチックセルを用いてNanoPhotometer(商標)により10秒ごとに、重合フィブリンの最大吸収波長(288 nm)における吸光度を測定した。各実験において、0秒の時点における吸光度を0として標準化し、他の各時点における相対的吸光度を決定した。
アプタマーおよび相補鎖解毒剤の添加濃度を表1の通りとし、13 nMトロンビンおよび2 mg/mLフィブリノゲンの最終濃度としたことを除き上記5.2.と同じように混合を行った。BFT IIアナライザーにより凝固時間の変化を測定した。
数値は平均±SDとして表された。群間の統計学的有意差は対応t検定により決定した。< 0.05のp値を統計学的に有意とみなした(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, *****p < 0.00001)。GraphPad Prism 6.0ソフトウェア(米国GraphPad Software社)を使用して分析を行った。
図1は、核酸アプタマーにフッ化スルホニル基(ウォーヘッド)を連結させる反応を経た後の反応混合物をHPLCで分析した結果を示す。図1において、未反応物、すなわちアルキニル基が連結されているがフッ化スルホニル基は連結されていないアプタマーに相当するピークを枠で囲っている。その枠の右隣に見られる大きなピークが反応物、すなわちフッ化スルホニル基がさらに連結されたアプタマーに相当する。トロンビン結合アプタマー(TBA)の、試験されたいずれの部位においても、精製することなく90%以上のウォーヘッド導入効率が得られたことがわかる。
Claims (14)
- 核酸アプタマーと、前記核酸アプタマーにアジド-アルキン間クリックケミストリー反応を介して連結されたフッ化スルホニル基とを含む、中和可能コバレントドラッグ化合物であって、
前記アプタマーと前記フッ化スルホニル基とが、前記アジド-アルキン間クリックケミストリー反応により形成される連結部分を含むリンカーによって連結されている、
中和可能コバレントドラッグ化合物。 - 前記リンカーが、-L1-Y-L2-という式で表わされ、ここで、Yは、前記アジド-アルキン間クリックケミストリー反応により形成される連結部分であり、L1は前記核酸アプタマーに結合する第1のリンカー部分であり、L2は前記フッ化スルホニル基に結合する第2のリンカー部分であり、
前記第2のリンカー部分のうち前記フッ化スルホニル基に結合する末端部分がアリーレンである、請求項1に記載の中和可能コバレントドラッグ化合物。 - 前記リンカーは、前記核酸アプタマー中の核酸塩基に結合している、請求項1~3のいずれか一項に記載の中和可能コバレントドラッグ化合物。
- 前記核酸アプタマーが、
5’-GGTTGGTGTGGTTGG-3’
の配列(配列番号1)を有するトロンビン結合アプタマーである、請求項1~4のいずれか一項に記載の中和可能コバレントドラッグ化合物。 - 請求項1~5のいずれか一項に記載の中和可能コバレントドラッグ化合物を含む医薬組成物。
- 請求項5に記載の中和可能コバレントドラッグ化合物を含む抗凝固剤。
- 患者における血液凝固を防止または抑制する方法における使用のための、請求項7に記載の抗凝固剤であって、前記方法は、前記患者に前記抗凝固剤を投与すること、および、前記抗凝固剤の投与後に、前記核酸アプタマーに対して相補的なオリゴヌクレオチドをさらに投与することを含む、抗凝固剤。
- 請求項1~5のいずれか一項に記載の化合物、請求項6に記載の組成物、または請求項7もしくは8に記載の抗凝固剤と、
前記核酸アプタマーに対して相補的なオリゴヌクレオチドと
を含む、
中和可能コバレントドラッグシステム。 - 標的蛋白質に対して共有結合を形成することができる中和可能コバレントドラッグの製造方法であって、
a)(a1)アルキニル基、シクロアルキニル基、もしくはヘテロシクロアルキニル基、または(a2)アジド基が連結または結合された、標的蛋白質に特異的な核酸アプタマー、および、
b)対応する(b1)アジド基、または(b2)アルキニル基、シクロアルキニル基、もしくはヘテロシクロアルキニル基とフッ化スルホニル基とが連結または結合された構造を有する、ウォーヘッド化合物
を反応させて、アジド-アルキン間クリックケミストリー反応を行い、前記アジド-アルキン間クリックケミストリー反応により形成された連結部分を含むリンカーを介して前記核酸アプタマーと前記フッ化スルホニル基とが連結された構造を取得することを含む、方法。 - 前記ウォーヘッド化合物は、前記フッ化スルホニル基と前記アジド基またはアルキニル基、シクロアルキニル基、もしくはヘテロシクロアルキニル基とを連結する第2のリンカーを含み、
前記第2のリンカーのうち前記フッ化スルホニル基に結合する末端部分がアリーレンである、
請求項10に記載の方法。 - 核酸アプタマーと、前記核酸アプタマーにリンカーを介して連結されたフッ化スルホニル基とを含み、前記リンカーのうち前記フッ化スルホニル基に結合する末端部分がアリーレンである、中和可能コバレントドラッグ化合物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/265,458 US20240033361A1 (en) | 2020-12-08 | 2021-10-28 | Neutralizable covalent drug |
JP2021576738A JP7029760B1 (ja) | 2020-12-08 | 2021-10-28 | 中和可能コバレントドラッグ |
EP21903051.7A EP4261285A1 (en) | 2020-12-08 | 2021-10-28 | Neutralizable covalent drug |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-203420 | 2020-12-08 | ||
JP2020203420 | 2020-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022123947A1 true WO2022123947A1 (ja) | 2022-06-16 |
Family
ID=81972909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/039891 WO2022123947A1 (ja) | 2020-12-08 | 2021-10-28 | 中和可能コバレントドラッグ |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022123947A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018003739A1 (ja) * | 2016-06-30 | 2018-01-04 | レナセラピューティクス株式会社 | 機能的リガンドを含む核酸複合体 |
JP2019196355A (ja) * | 2013-08-08 | 2019-11-14 | ザ スクリップス リサーチ インスティテュートThe Scrippsresearch Institute | 非天然ヌクレオチドの取り込みによるインビトロの核酸の部位特異的な酵素標識のための方法 |
JP2020534345A (ja) * | 2017-09-22 | 2020-11-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 親和性タグ付き光スイッチ及びその使用方法 |
-
2021
- 2021-10-28 WO PCT/JP2021/039891 patent/WO2022123947A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019196355A (ja) * | 2013-08-08 | 2019-11-14 | ザ スクリップス リサーチ インスティテュートThe Scrippsresearch Institute | 非天然ヌクレオチドの取り込みによるインビトロの核酸の部位特異的な酵素標識のための方法 |
WO2018003739A1 (ja) * | 2016-06-30 | 2018-01-04 | レナセラピューティクス株式会社 | 機能的リガンドを含む核酸複合体 |
JP2020534345A (ja) * | 2017-09-22 | 2020-11-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 親和性タグ付き光スイッチ及びその使用方法 |
Non-Patent Citations (14)
Title |
---|
"Doctoral dissertation and examination results", 25 September 2018, HOKKAIDO UNIVERSITY, Japan, article SHISHIDO, YUKO: "Inventive Research on Covalent Ligands Using Sulfonyl Fluoride Reactions (Abstract)", pages: 1 - 3, XP009538192 * |
BAUER, R. A.: "Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies", DRUG DISCOV TODAY, vol. 20, no. 9, 2015, pages 1061 - 73 |
BOCK ET AL., NATURE, vol. 355, 1992, pages 564 - 566 |
BOMPIANI ET AL., CURR PHARM BIOTECHNOL, vol. 13, no. 10, 2012, pages 1924 - 34 |
GAMBINI, L.BAGGIO, C.UDOMPHOLKUL, P.JOSSART, J.SALEM, A. F.PERRY, J. J. P.PELLECCHIA, M.: "Covalent Inhibitors of Protein-Protein Interactions Targeting Lysine, Tyrosine, or Histidine Residues", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 11, 2019, pages 5616 - 5627, XP055898707, DOI: 10.1021/acs.jmedchem.9b00561 |
NAGATOISHI ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 352, 2007, pages 812 - 817 |
NARAYANAN ARJUN, JONES LYN H.: "Sulfonyl fluorides as privileged warheads in chemical biology", CHEMICAL SCIENCE, vol. 6, no. 5, 1 January 2015 (2015-01-01), United Kingdom , pages 2650 - 2659, XP055796185, ISSN: 2041-6520, DOI: 10.1039/C5SC00408J * |
NARAYANAN ET AL., CHEMICAL SCIENCE, vol. 6, no. 5, 2015, pages 2650 - 2659 |
RUSCONI ET AL., NAT BIOTECHNOL, vol. 22, no. 11, 2004, pages 1423 - 8 |
SINGH, J.PETTER, R. C.BAILLIE, T. A.WHITTY, A.: "The resurgence of covalent drugs", NAT REV DRUG DISCOV, vol. 10, no. 4, 2011, pages 307 - 17, XP037083900, DOI: 10.1038/nrd3410 |
SONG ET AL., ANAL. CHEM., vol. 92, 2020, pages 9895 - 9900 |
STOLL ET AL., MOLECULES, vol. 22, no. 6, 2017, pages 954 |
TABUCHI YUDAI, YANG JAY, TAKI MASUMI: "Inhibition of thrombin activity by a covalent-binding aptamer and reversal by the complementary strand antidote", CHEMICAL COMMUNICATIONS, vol. 57, no. 20, 9 March 2021 (2021-03-09), UK , pages 2483 - 2486, XP055941941, ISSN: 1359-7345, DOI: 10.1039/D0CC08109D * |
ZHOU ET AL., NAT REV DRUG DISCOV, vol. 16, no. 3, 2017, pages 181 - 202 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5242918B2 (ja) | 補体関連障害の治療に有用なアプタマー治療法 | |
KR101185050B1 (ko) | 응고 인자의 개선된 모듈레이터 | |
TW201642874A (zh) | 抑制因子xii基因表現之組合物及方法 | |
WO2012050611A2 (en) | Aptamers to glycoprotein vi | |
KR20080042091A (ko) | 고 친화도로 트롬빈에 결합하는 앱타머 | |
WO2023169548A1 (zh) | Lpa抑制剂及其用途 | |
Astakhova et al. | Peptide–LNA oligonucleotide conjugates | |
JP7029760B1 (ja) | 中和可能コバレントドラッグ | |
JP2006507812A (ja) | オリゴヌクレオチド結合体 | |
KR20200136363A (ko) | 헤어핀형 1개쇄 rna 분자의 제조 방법 | |
WO2022232195A2 (en) | Covalent aptamers | |
WO2024088190A1 (zh) | 一种抑制lpa基因表达的rna抑制剂及其应用 | |
WO2015117206A1 (en) | Improved aptamers | |
TW202227135A (zh) | 用於遞送治療劑之脂質結合物 | |
JPWO2006080262A1 (ja) | Age−2アプタマー | |
Honcharenko et al. | New alkyne and amine linkers for versatile multiple conjugation of oligonucleotides | |
Esawi et al. | Clinical use and future perspective of aptamers | |
WO2022123947A1 (ja) | 中和可能コバレントドラッグ | |
Gauthier et al. | Gymnotic delivery and gene silencing activity of reduction-responsive siRNAs bearing lipophilic disulfide-containing modifications at 2′-position | |
TW202345865A (zh) | 抑制LPA(Apo(a))蛋白表達的組合物和方法 | |
WO2022220216A1 (ja) | アプタマー型マルチウォーヘッド共有結合性薬剤 | |
US20220170062A1 (en) | Rna capping method, production method for modified rna, and modified rna | |
CN101501056A (zh) | 以高亲和力结合凝血酶的适体 | |
WO2005035546A1 (en) | Peptide nucleic acid conjugates and uses thereof | |
HUT77034A (hu) | Ribonukleinsavak hasítására szolgáló oligonukleotid konjugátumok, készítmények és eljárás |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2021576738 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21903051 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18265458 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021903051 Country of ref document: EP Effective date: 20230710 |